Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 11q22 2q22 3 Microdeletion Syndrome C5680062
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 11q22 2q22 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
11q22 2q22 3 Microdeletion Syndrome C5680062
A rare genetic condition where a small segment of chromosome 11 is missing. It can affect development and cause various health concerns. Treatment focuses on managing specific symptoms with supportive care.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
11q22 2q22 3 Microdeletion Syndrome C5680062
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
11q22 2q22 3 Microdeletion Syndrome C5680062
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
11q22 2q22 3 Microdeletion Syndrome C5680062
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
11q22 2q22 3 Microdeletion Syndrome C5680062
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
11q22 2q22 3 Microdeletion Syndrome C5680062
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 11q22-2q22-3-microdeletion-syndrome-C5680062 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is described and may begin in childhood or adolescence. | Hypertension is not established from the supplied description. | Moderate |
| Puberty and genitalia | Absent puberty and ambiguous genitalia are described. | These features are not established; developmental concerns may occur. | High |
| Development | Primary developmental delay is not established by the source. | Development may be affected, with variable health concerns. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with disordered puberty
This pattern fits the described steroid-production disorder better than a nonspecific microdeletion.
Moderate
Ambiguous genitalia
Genital ambiguity is specifically described for the left condition.
Moderate
Suspected adrenal steroid defect
Endocrine evaluation is appropriate when steroid synthesis is the leading concern.
High
Choose 11q22 2q22 3 Microdeletion Syndrome C5680062 when
Multiple congenital or developmental findings
A chromosomal microdeletion is more consistent with broad developmental effects.
Moderate
No clear steroid-disorder pattern
Absence of the described endocrine pattern lowers support for the left diagnosis.
Low
Need for syndrome-level genetic assessment
Chromosomal testing can evaluate a suspected missing chromosome 11 segment.
High
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 11q22 2q22 3 Microdeletion Syndrome C5680062 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal steroid production is expected, but exact cutoffs are not supplied. | No characteristic steroid pattern is established. | An abnormal result supports endocrine evaluation; it is not itself a diagnosis. |
| Blood pressure measurement | Hypertension may be present. | No specific blood-pressure pattern is established. | Blood pressure helps assessment but cannot distinguish the conditions alone. |
| Chromosomal microarray | A chromosome 11 microdeletion is not the described cause. | May identify the missing 11q22.2–q22.3 segment. | Genetic confirmation requires qualified laboratory and clinician review. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic and described as severe; survival and complication rates are not established here.
- Factors
- Blood-pressure control, hormone replacement, and puberty-related care may influence course.
11q22 2q22 3 Microdeletion Syndrome C5680062
- Outcome
- Chronic and described as moderate, with variable developmental and health effects.
- Factors
- Specific symptoms, developmental needs, and available supportive services influence course.
Time frame: Childhood onset is described for the left; timing for the right is not fully specified.
Prognosis cannot be individualized from these sparse descriptions.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related harm | High blood pressure is a described concern. Not established from the source. Monitoring is prudent; complication rates are not supplied. |
| Pubertal or reproductive effects | Lack of puberty and genital ambiguity are described. Specific reproductive effects are not established. Specialist assessment is needed; outcomes vary. |
| Developmental health needs | Not a primary feature in the source. Development and varied health concerns may require support. Needs are individualized and not fully defined here. |
Patient education highlights
- HighDiagnosis confirmation
Neither label should be assumed from symptoms alone; genetic and endocrine results need clinician interpretation.
- HighLong-term care
The steroid disorder may require lifelong hormone replacement; the microdeletion is managed supportively by symptoms.
- MediumInheritance and family questions
Both are genetic, but inheritance details and recurrence risk are not established in this source.